Evidence map›Paper›PMID 41884769›Full record

ArticleKidney medicine2026

Fibrillary Glomerulonephritis and Apolipoprotein A-IV Amyloidosis: A Rare Dual Pathology Diagnosed by Mass Spectrometry and DNAJB9 Immunohistochemistry.

Sumaiya Ahmed, Mark Canney, Ginette Starkell, David Massicotte-Azarniouch

Abstract readCase Reports
In one paragraph

Article in Kidney medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sumaiya AhmedSchool of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada.
Mark CanneyDivision of Nephrology, Department of Medicine, The Ottawa Hospital, Ottawa, ON, Canada.
Ginette StarkellDepartment of Diagnostic and Molecular Pathology, The Ottawa Hospital, Ottawa, ON, Canada.
David Massicotte-AzarniouchDivision of Nephrology, Department of Medicine, The Ottawa Hospital, Ottawa, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fibrillary glomerulonephritis is a rare cause of proteinuric kidney disease characterized by Congo red-negative fibrillary deposits and typically shows DNAJB9 positivity on immunohistochemistry. Amyloidosis is defined by Congo red positivity and can be typed by laser microdissection-tandem mass spectrometry when routine studies are inconclusive. We report the case of a 64-year-old man with proteinuria and declining kidney function whose kidney biopsy showed DNAJB9-positive fibrillary glomerulonephritis in glomeruli, but Congo red-positive deposits confined to the medulla were DNAJB9 negative. Laser microdissection-tandem mass spectrometry of the medullary deposits identified apolipoprotein A-IV amyloidosis, establishing concurrent fibrillary glomerulonephritis and apolipoprotein A-IV amyloidosis in the same biopsy. Apolipoprotein A-IV amyloidosis is often medullary predominant and, in rare hereditary forms related to autosomal dominant

Indexed as

Apolipoprotein A-IV amyloidosisCongo redDNAJB9fibrillary glomerulonephritiskidney biopsylaser microdissection–tandem mass spectrometry

Identifiers

PMID41884769
PMCPMC13010398

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.